What is Kymera Therapeutics's revenue?

Kymera Therapeutics (KYMR) generated $51.5M in revenue over the trailing twelve months, down 12.6% year over year.

Is Kymera Therapeutics profitable?

Kymera Therapeutics is not currently profitable: it reported a net loss of $315.0M over the trailing twelve months, a -612.0% net margin.

What is Kymera Therapeutics's earnings per share?

Kymera Therapeutics's diluted EPS over the trailing twelve months is $-3.58.

Where does Kymera Therapeutics's income statement data come from?

Every line is extracted from Kymera Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Kymera Therapeutics KYMR Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Total revenue	$39.21M-16.7%	$47.07M-40.1%	$78.59M+67.8%	$46.83M-35.7%
Research and development	$316.57M+31.8%	$240.25M+27.1%	$189.08M+15.1%	$164.25M+19.9%
General and administrative	$68.19M+7.3%	$63.53M+15.4%	$55.04M+25.6%	$43.83M+20.6%
Impairment charges	$3.86M-21.7%	$4.93M—	$0—	$0—
Other operating expenses	$388.61M+25.9%	$308.71M+26.5%	$244.12M+17.3%	$208.08M+20.0%
Total operating expenses	$388.61M+25.9%	$308.71M+26.5%	$244.12M+17.3%	$208.08M+20.0%
Operating income	-$349.4M-33.5%	-$261.64M-58.1%	-$165.53M-2.7%	-$161.26M-60.4%
Operating margin	-891.1%-335pp	-555.8%-345pp	-210.6%+134pp	-344.4%-206pp
Other income (expense), net	$38.05M+0.7%	$37.78M+103%	$18.57M+188%	$6.45M+1,960%
Net income	-$311.35M-39.1%	-$223.86M-52.3%	-$146.96M+5.1%	-$154.81M-54.5%
Net margin	-794.1%-318pp	-475.6%-289pp	-187%+144pp	-330.6%-193pp
Diluted earnings per share	-$3.69-23.8%	-$2.98-18.3%	-$2.52+12.2%	-$2.87-38.6%
Basic earnings per share	-$3.69-23.8%	-$2.98-18.3%	-$2.52+12.2%	-$2.87-37.3%
Weighted-average shares, diluted	332.4M+12.7%	295M+26.4%	233.3M+10.1%	211.9M+12.4%
Weighted-average shares, basic	332.4M+12.7%	295M+26.4%	233.3M+10.1%	211.9M—
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$308.07M-37.0%	-$224.79M-57.7%	-$142.57M+10.4%	-$159.1M-57.9%
Other Nonoperating Expense	$368K+47.8%	$249K+27.0%	$196K+10.7%	$177K+2.3%
Other Nonoperating Income	$38.42M+1.0%	$38.03M+103%	$18.76M+183%	$6.62M+1,263%
Other income, net (Note 6)	$38.05M+0.7%	$37.78M+103%	$18.57M+188%	$6.45M+1,960%
Revenue From Contract With Customer Excluding Assessed Tax	$39.21M-16.7%	$47.07M-40.1%	$78.59M+67.8%	$46.83M-35.7%
EBIT	-$349.4M-33.5%	-$261.64M-58.1%	-$165.53M-2.7%	-$161.26M-60.4%
EBITDA	-$341.09M-34.1%	-$254.26M-57.0%	-$161.97M-2.3%	-$158.28M-61.3%
EBITDA	-$341.09M-34.1%	-$254.26M-57.0%	-$161.97M-2.3%	-$158.28M-61.3%
EBITDA margin	-869.9%-330pp	-540.2%-334pp	-206.1%+132pp	-338%-203pp
EBIT	-$349.4M-33.5%	-$261.64M-58.1%	-$165.53M-2.7%	-$161.26M-60.4%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Kymera Therapeutics.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Kymera Therapeutics's revenue?: Kymera Therapeutics (KYMR) generated $51.5M in revenue over the trailing twelve months, down 12.6% year over year.
Is Kymera Therapeutics profitable?: Kymera Therapeutics is not currently profitable: it reported a net loss of $315.0M over the trailing twelve months, a -612.0% net margin.
What is Kymera Therapeutics's earnings per share?: Kymera Therapeutics's diluted EPS over the trailing twelve months is $-3.58.
Where does Kymera Therapeutics's income statement data come from?: Every line is extracted from Kymera Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.